AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04504383 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by the oral route BID for 12 weeks.
Study NCT02438748 — intervention group
Intervention type: DEVICE
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: A non-invasive method of brain stimulation.
Study NCT02189421 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ultra-slim upper endoscope
Description: Direct peroral cholangioscopy by using an ultra-slim upper endoscope without assisting accessories
Study NCT03321669 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Capsule endoscopy
Description: Ingestion of capsule endoscopy for the diagnosis of small bowel lesions
Study NCT03321669 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Capsule endoscopy
Description: Ingestion of capsule endoscopy for the diagnosis of small bowel lesions
Study NCT00966238 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAX125
Description: STF2.HA1(SI) (VAX125), which is a recombinant fusion protein that consists of Salmonella typhimurium flagellin type 2 (STF2), a Toll-like receptor 5 (TLR5) ligand, fused at its C-terminus to the globular head domain of the hemagglutinin (HA) antigen of influenza A HA1 Solomon Islands (SI).
Study NCT00524446 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk-containing fortified spread
Description: Counseling + Vitamin A as for ST-DI + 750 g of fortified spread (FSm) 2-weekly (54 g / day) between 6 and 18 months of age.
Study NCT00524446 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy-containing fortified spread
Description: Counseling + Vitamin A as for ST-DI + 750 g of modified fortified spread (FSs) 2-weekly (54 g / day) between 6 and 18 months of age.
Study NCT00524446 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Maize-soy flour
Description: Counseling + Vitamin A as for ST_DI + 1 kg fortified maize / soy flour 2-weekly (71 g / day) between 6 and 18 months of age.
Study NCT05920434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: randomized controlled study
Description: randomized controlled study,no drugs or devices were administered to the participants.
Study NCT04372602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvelisib
Description: -For patients unable to administer orally, a duvelisib suspension will be administered through a nasogastric/orogastric tube.
Study NCT04372602 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood draw
Description: * First 10 patients enrolled~* Screening, Day 2, Day 4, Day 8, Day 10, Day 15, and Day 29
Study NCT04372602 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Peripheral blood draw
Description: * First 10 patients enrolled~* Screening, Day 2, Day 4, Day 8, Day 10, Day 15, and Day 29
Study NCT04372602 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: -Provided by Verastem
Study NCT01438320 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Quercetin
Description: Bioflavonoid
Study NCT01505127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Study NCT01505127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Study NCT01505127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Study NCT01505127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Study NCT02739191 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICO, Smith & Nephew
Description: Direct application of negative pressure wound therapy following Foot and Ankle surgery
Study NCT04464681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M201-A Injection
Description: Active Substance: M201-A Route of administration: continuous intravenous injection
Study NCT04464681 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: M201-A Placebo Route of administration: continuous intravenous injection
Study NCT03463889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68-labeled PSMA-11
Description: Given IV
Study NCT03463889 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI in combination with PET
Study NCT03463889 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)
Description: Undergo PET in combination with MRI
Study NCT02235376 — intervention group
Intervention type: OTHER
Intervention: weaning trial of mechanical ventilation
Study NCT02474095 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02474095 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02474095 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Acupoint Electrical Stimulation
Description: Undergo ALTENS
Study NCT02474095 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Acupoint Electrical Stimulation
Description: Undergo ALTENS
Study NCT02073279 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Satralizumab
Description: Satralizumab will be administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).
Study NCT02073279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satralizumab
Description: Satralizumab will be administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).
Study NCT02073279 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).
Study NCT02151526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LentiGlobin BB305 Drug Product
Description: LentiGlobin BB305 Drug Product was administered by intravenous (IV) infusion.
Study NCT00283933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: migalastat HCl
Study NCT02889640 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SAGA Innovations
Description: An intensive math tutoring program
Study NCT02889640 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scale-up tutors
Description: Tutors who have been selected for hire via the one in three-and-a-half randomization process
Study NCT02889640 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Tutors
Description: Tutors who have been selected for hire via SAGA's standard hiring process, which does not entail randomization
Study NCT02946060 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Audiobooks
Description: iPods with audiobooks
Study NCT02946060 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tempo-pace synchronized playlists
Description: Playlists with or without RAS
Study NCT02946060 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Usual Care
Description: iPods containing either a silent track or white noise
Study NCT03414346 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exclusively ice pack
Description: Each subject will receive an experimental intervention of exclusively 500 grams of crushed ice. The intervention will last 20 minutes, and the order of application, expressed in % of water X ice, will be according to the randomization (realized in the first day). The pack will be wrapped in a band for improvement of the contac area. The subject will be asked to mark his pain level on the visual analogue scale (no pain score of 0 and pain as bad as it could be score of 10) every minute until the total time of the intervention.
Study NCT03414346 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ice pack added 10% of water
Description: Each subject will receive an experimental intervention of ice pack added to 50 mL of water. The intervention will last 20 minutes, and the order of application, expressed in % of water X ice, will be according to the randomization (realized in the first day). The pack will be wrapped in a band for improvement of the contac area. The subject will be asked to mark his pain level on the visual analogue scale (no pain score of 0 and pain as bad as it could be score of 10) every minute until the total time of the intervention.
Study NCT03414346 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ice pack added 100% of water
Description: Each subject will receive an experimental intervention of ice pack added to 500 mL of water. The intervention will last 20 minutes, and the order of application, expressed in % of water X ice, will be according to the randomization (realized in the first day). The pack will be wrapped in a band for improvement of the contac area. The subject will be asked to mark his pain level on the visual analogue scale (no pain score of 0 and pain as bad as it could be score of 10) every minute until the total time of the intervention.
Study NCT00847444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug-based intervention
Description: Randomization A AA: 3 cycles of 5-Fluorouracil 500 mg/m² i.v. body surface area and Epirubicine 100 mg/m² i.v. and Cyclophosphamide 500 mg/m² i.v., (FEC100), each administered on day 1, repeated on day 22, subsequently followed by 3 cycles of Docetaxel 100 mg/m² body surface area i.v. (D), administered on day 1, repeated on day 22 AB: 6 cycles of Docetaxel 75 mg/m² and Cyclophosphamide 600 mg/m² i.v. body surface area i.v. (DC), administered on day 1, repeated on day 22
Study NCT00847444 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle-based Intervention
Description: All Patients with a Body Mass Index (BMI) of 24 - 40 kg/m² at the time of enrollment will be subsequently randomized as follows:~Second randomization B BA: Lifestyle intervention program to reduce body weight comprising individual weight loss, diet and physical activity goals in the framework of a 2-year standardized and structured telephone and mail-based intervention.
Study NCT02214121 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ticagrelor Dose 1a + Dose 2a
Description: Ticagrelor Dose 1a and ticagrelor Dose 2a single doses + 1 week ticagrelor repeated dosing followed by 4 weeks repeated dosing ticagrelor or placebo.
Study NCT02214121 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ticagrelor Dose 1b + Dose 2b
Description: Ticagrelor Dose 1b and ticagrelor Dose 2b single doses + 1 week ticagrelor repeted dosing followed by 4 weeks repeated dosing ticagrelor or placebo.
Study NCT02403908 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nMARQ Circular and Crescent catheters
Description: Radiofrequency denervation of right and left pulmonary arteries ostia and of main pulmonary artery \<2 mm proximal from both ostia of right and left pulmonary arteries.
Study NCT02187328 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Description: Volunteers participate in two visits at least 5 days apart. The day of their visit they ingest 12.5 oz of grapefruit juice in the morning and 12.5 oz of grapefruit juice ingested in the afternoon, 3h before reporting to the laboratory. The order of the visits is randomized, one visit volunteers ingest apple juice only, the other visit grapefruit juice only
Study NCT02187328 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Apple juice
Description: Volunteers participate in two visits at least 5 days apart. The day of their visit they ingest 12.5 oz of grapefruit juice or Apple juice ingested in the morning and 12.5 oz of grapefruit juice ingested in the afternoon, 3h before reporting to the laboratory. The order of the visits is randomized, one visit volunteers ingest apple juice only, the other visit grapefruit juice only
Study NCT01779193 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: lactic acid bacteria
Description: oral lactobacillus capsule (dose of 2 \* 10\^9 cfu per capsule), one pill daily
Study NCT01779193 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cranberry
Description: oral cranberry capsule, one pill daily
Study NCT01779193 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cranberry
Description: oral cranberry capsule, one pill daily
Study NCT01779193 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsule without lactic acid bacteria and cranberry, one pill daily
Study NCT04090554 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Cytosponge™
Description: The device consists of a spherical mesh enclosed in a gelatine capsule and attached to a string. The capsule is swallowed and allowed to reach the stomach . In the stomach the capsule is left for up to 5 minutes where it dissolves allowing the sponge to expand to its full size. It is then withdrawn using the suture, and as it does so collects cells from the lining of the oesophagus.
Study NCT00545714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m\^2 as IV infusion will be administered on Days 1-3 of first six 28-day cycles.
Study NCT00545714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m\^2 as IV infusion will be administered on Day 0 of Cycle 1; 500 mg/m\^2 as IV infusion will be administered on Day 1 of Cycle 2-6; and 375 mg/m\^2 as IV infusion every 2 months from 3 months after Day 1 Cycle 6 up to a total of 18 doses or up to 3 years after Cycle 6.
Study NCT03869944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine Oral Solution
Description: During the EPI-2 visit, HIV-1 negative children of mothers with a unsuppressed plasma HIV-1 VL (≥ 1000 copies/mL) will be initiated on PrEP, lamivudine syrup (7.5 mg twice daily if 2 to 4 kg; 25 mg twice a day if weight \<8 kg; and 50 mg twice a day if weight >8 kg) for 10 months, until the child is 12 months old. A monitoring on the mother's VL and child's diagnosis will take place at 6 and 12 months.~Mothers with unsuppressed plasma HIV-1 VL (\< 1000 copies/mL) and HIV-1 negative children will not be offered PrEP but the mother's VL and child diagnosis will be monitored at 6 and 12 months: If the VL is ≥ 1000 copies/mL, the child will be initiated on PrEP until the child is 12 months old.~Children infected with HIV-1 will be referred to the National Program for immediate ART.
Study NCT04154631 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)
Description: TranS-C is a psychosocial treatment designed to improve sleep and circadian functioning. It is a modular, psychosocial, skills-based approach. In this study, two version of TranS-C will be tested: Standard and Adapted.
Study NCT04154631 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)
Description: The Adapted version was derived from Standard TranS-C. It was developed to improve the fit of the treatment with the CMHC context.
Study NCT04154631 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Delayed Treatment
Description: Usual care in the partner CMHCs typically starts with a case manager who co-ordinates care and refers each client for a medication review and to various rehabilitation programs (e.g., health care, housing, nutrition, finding a job, peer monitoring).
Study NCT04262648 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus Reuteri
Description: Lactobacillus Reuteri NCIMB 30351
Study NCT04262648 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sunflower oil
Study NCT02749500 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Occupational Therapy (OT)
Description: Standard of care occupational therapy for stroke recovery
Study NCT04409262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants will receive IV placebo matched to TCZ
Study NCT02749500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Occupational Therapy (OT)
Description: Standard of care occupational therapy for stroke recovery
Study NCT02749500 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: m2 BAT
Description: Conventional OT plus 1 hour additional bimanual-to-unimanual device-assisted therapy.
Study NCT00401661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfuzosin
Description: One tablet of 10mg once daily at the end of evening meal
Study NCT02087657 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Administration of hyperbaric oxygen
Description: Hyperbaric oxygen at 2.5 atmospheres absolute (ATA) for a total of 2 hours
Study NCT02287714 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Instep without gastrocnemius recession
Description: Patient will receive an instep plantar fascial release without gastrocnemius recession.
Study NCT02287714 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Instep with gastrocnemius recession
Description: Patient will receive an instep plantar fascial release as well as gastrocnemius recession.
Study NCT01546428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INC280
Study NCT02712723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Nonsteroidal aromatase inhibitor
Study NCT02712723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Nonsteroidal aromatase inhibitor
Study NCT01597713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC 0148-0000-0362
Description: Subjects will be randomised to receive a single dose of NNC 0148-0000-0362 orally within each dose group
Study NCT01597713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: As an active comparator, one standard dose will be given subcutaneously (s.c., under the skin) within each dose group
Study NCT02712723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Oral cyclin-dependent kinase (CDK) inhibitor
Study NCT02712723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo for ribociclib
Study NCT01597713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Subjects will receive a single dose of oral placebo within each dose group
Study NCT01597713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC 0148-0000-0362
Description: Single low dose administered orally in randomised order on three dosing visits separated by a wash-out period
Study NCT01385774 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Transluminal Angioplasty
Description: The Percutaneous Transluminal Angioplasty (PTA) procedure will be performed by an experienced interventional radiologist using a conventional guide wire and balloon catheter technique. A stent will be placed in cases in which the residual mean pressure gradient is greater than 10 mmHg across the treated site or when more than 30% stenosis after the procedure is detected. All PTA patients are encouraged perform at least three walking sessions every day.
Study NCT01385774 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised Exercise Therapy
Description: Supervised Exercise Therapy (SET) will take place in the hospital or community based according to the guidelines of the Dutch Society for Physiotherapists. The duration of the treatment will be at least 6 months and with a frequency of 2 times a week for at least 60 minutes and an intensity near maximum pain barrier (defined as pain of which it is not possible to be distracted). The frequency of the training will decrease after 3 months and the patients will receive homework, make a plan and keep a log of their exercise activities. Furthermore the program consists of walking pattern improvement and enhancement of endurance and strength. All SET patients are encouraged to perform at least three walking sessions every day on their own.
Study NCT00054405 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interleukin-12
Description: Given IV
Study NCT00054405 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given IV
Study NCT01597713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC 0148-0000-0362
Description: Single high dose administered i.v. in randomised order on three dosing visits separated by a wash-out period
Study NCT01597713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC 0148-0000-0362
Description: Single high dose administered orally in randomised order on three dosing visits separated by a wash-out period
Study NCT02219412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ticagrelor
Description: 90 mg bid for 2 weeks
Study NCT04047979 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shingrix®
Description: A zoster vaccine recombinant, adjuvanted, recently approved by the FDA for prevention of herpes zoster (shingles) in adults aged 50 years and older. It is given in two doses (0.5 mL each): at 0 and 2 to 6 months.
Study NCT02251938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-109 440 μg
Description: Medium Dose